openPR Logo
Press release

US Breast Cancer Drug Market Outlook 2022 Report

05-07-2018 07:16 AM CET | Health & Medicine

Press release from: Kuick Resarch

“US Breast Cancer Drug Market Outlook 2022” Report Highlights:

* US Breast Cancer Tendencies
* US Breast Cancer Drug Market Outline
* US Breast Cancer Drug Market Dynamics
* Breast Cancer Risk Undercurrents
* US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis
* US Breast Cancer Marketed Drugs Clinical Insight: 18 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-US-Breast-Cancer-Drug-Market-Outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. US Cancer Prevalence Rate

1.1 Overview

1.2 Glimpse of Past Cancer Incidences

1.3 Current Drifts in Cancer Frequencies

1.4 Estimated Future Cancer Occurrences



2. US Breast Cancer Tendencies

2.1 Indication

2.2 Breast Cancer Historical Incidences

2.3 Recent inclinations in Breast Cancer

2.4 Breast Cancer Frequencies over Age & Race



3. Breast Cancer Risk Undercurrents

3.1 Hormonal Aspects

3.2 Family History & Genetic Predisposition

3.3 Cumulative Age & Elevated Risk

3.4 Management of Breast Cancer



4. US Breast Cancer Drug Market Outline

4.1 Topographical Arcade Sales

4.2 HER-2 Positive Drug Market



5. US Breast Cancer Drug Market Dynamics

5.1 Breast Cancer Market Accelerative Parameters

5.2 Breast Cancer Market Challenges



6. US Breast Cancer Drug Market Future Aspects



US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis



7. Eribulin (Halaven)

7.1 Clinical Introduction

7.2 Brand Names

7.3 Recording & Reporting Of Clinical Adverse Events



8. Trastuzumab Emtansine (Kadcyla)

8.1 Clinical Introduction

8.2 Brand Names

8.3 Recording & Reporting Of Clinical Adverse Events



9. Palbociclib (Ibrance)

9.1 Clinical Introduction

9.2 Brand Names

9.3 Recording & Reporting Of Clinical Adverse Events



10. Pertuzumab (Omnitarg & Perjeta)

10.1 Clinical Introduction

10.2 Brand Names

10.3 Recording & Reporting Of Clinical Adverse Events



11. Gadobutrol (Gadavist, Gadovist & Gadovist 1.0)

11.1 Clinical Introduction

11.2 Brand Names

11.3 Recording & Reporting Of Clinical Adverse Events



12. Lapatinib (Tykerb)

12.1 Clinical Introduction

12.2 Brand Names

12.3 Recording & Reporting Of Clinical Adverse Events



13. Tamoxifen Oral Liquid (Soltamox)

13.1 Clinical Introduction

13.2 Brand Names

13.3 Recording & Reporting Of Clinical Adverse Events



14. Fulvestrant (Faslodex)

14.1 Clinical Introduction

14.2 Brand Names

14.3 Recording & Reporting Of Clinical Adverse Events



15. Anastrozole (Arimidex)

15.1 Clinical Introduction

15.2 Brand Names

15.3 Recording & Reporting Of Clinical Adverse Events



16. Ixabepilone (Ixempra)

16.1 Clinical Introduction

16.2 Brand Names

16.3 Recording & Reporting Of Clinical Adverse Events



17. Toremifene (Fareston)

17.1 Clinical Introduction

17.2 Brand Names

17.3 Recording & Reporting Of Clinical Adverse Events



18. Letrozole (Femara)

18.1 Clinical Introduction

18.2 Brand Names

18.3 Recording & Reporting Of Clinical Adverse Events



19. Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))

19.1 Clinical Introduction

19.2 Brand Names



20. Exemestane (Aromasin)

20.1 Clinical Introduction

20.2 Brand Names

20.3 Recording & Reporting Of Clinical Adverse Events



21. Vitamin B12 Fluorescent-Analogues (CobalaFluor Green & CobalaFluor Red)

21.1 Clinical Introduction

21.2 Brand Names



22. Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)

22.1 Clinical Introduction

22.2 Brand Names



23. Fluoxymesterone

23.1 Clinical Introduction

23.2 Recording & Reporting Of Clinical Adverse Events



24. Competitive Landscape

24.1 Agilent Technologies

24.2 AstraZeneca

24.3 Bayer HealthCare Pharmaceuticals

24.4 Bristol-Myers Squibb

24.5 Eisai Co Ltd

24.6 Eli Lilly

24.7 Novartis

24.8 Onyx Pharmaceuticals

24.9 Orion

24.10 Perrigo

24.11 Pfizer

24.12 Roche

Figure 1-1: Top Ten Countries in Cancer Incidence Trends

Figure 1-2: Global - Reported Deaths for the Leading Cancers in Men, 2012

Figure 1-3: US - Estimated Number of New Cancer Cases by Sex, 2016

Figure 2-1: Relationship between Age & Breast Cancer

Figure 2-2: Prevalence of Female Breast Cancer According to Ethnicity

Figure 3-1: Various Risk Factors Associated With Breast Cancer

Figure 4-1: Estimated Breast Cancer Deaths in North East Of US, 2016

Figure 4-2: HER-2 Positive Receptor & Herceptin

Figure 5-1: Accelerative Parameters of Breast Cancer Market

Figure 5-2: Current Challenges in Breast Cancer Therapeutics

Figure 8-1: Kadcyla - US Sales (Million US$), 2013-2022

Figure 8-2: Kadcyla - Global Sales (Million US$), 2013-2022

Figure 9-1: Ibrance - US Sales (Million US$), 2015-2022

Figure 9-2: Ibrance - Global Sales (Million US$), 2015-2022

Figure 10-1: Omnitarg- US Sales (Million US$), 2015-2022

Figure 10-2: Omnitarg / Perjeta - Global Sales (Million US$), 2015-2022

Figure 11-1: Gadavist - US Sales (Million US$), 2015-2022

Figure 11-2: Gadavist - Global Sales (Million US$), 2015-2022

Figure 12-1: Tykerb - US Sales (Million US$), 2015-2022

Figure 12-2: Tykerb - Global Sales (Million US$), 2015-2022

Figure 15-1: Arimidex - US Sales (Million US$), 2015-2022

Figure 15-2: Arimidex - Global Sales (Million US$), 2015-2022

Figure 16-1: Ixempra - US Sales (Million US$), 2015-2022

Figure 16-2: Ixempra - Global Sales (Million US$), 2015-2022

Figure 18-1: Femara - US Sales (Million US$), 2015-2022

Figure 18-2: Femara - Global Sales (Million US$), 2015-2022

Figure 24-1: Novartis - Clinical Pipeline

Figure 24-2: Roche - Clinical Pipeline



Table 1-1: US - Estimated Number* of New Cancer Cases and Deaths by Sex, 2016

Table 1-2: US - Estimated Number* of New Cases for Selected Cancers by State, 2016

Table 1-3: US - Estimated Number* of Deaths for Selected Cancers by State, 2016

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Breast Cancer Drug Market Outlook 2022 Report here

News-ID: 1040753 • Views: 226

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Cancer

Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and